Bora Pharmaceuticals Co., Ltd. has partnered with Accord BioPharma to manufacture pre-filled syringes of UDENYCA (pegfilgrastim-cbqv), a product recently added to Accord’s portfolio. Leveraging its Groninger FlexPro 50 Isolator Line for vials and pre-filled syringes at its Baltimore site Bora will help scale supply of a vital therapy to support immune health in cancer care.

Bora combines its CDMO expertise in aseptic fill/finish capabilities for vials and pre-filled syringes with the latest isolator technology and industry knowledge to support key partners, including Accord BioPharma, Inc., with large-scale production of critical therapies.

“We’re excited to combine Bora’s manufacturing expertise with Accord’s desire to increase production to meet demand and manufacture in the United States.” said David Fidler, Vice President and General Manager of Bora Pharmaceuticals Baltimore. “Our team’s deep technical knowledge will play a vital role in accomplishing these goals.”

Bora provides services from early development and scale-up to process optimization and commercial manufacturing.